glp-1 zepbound FDA approval for (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and hormone receptors - Eli Lilly Eli Lilly strikes Zepbound deal

Data Source: IRIS by Real Chemistry | Image Credit: Real Chemistry Medicaid spending on GLP-1s has grown exponentially over the past five years, reflecting both an increase in GLP-1 usage and expanded coverage in many states

Ladiges, "The potential of GHK as an anti-aging peptide," Aging Pathobiol

Por esse motivo, esses medicamentos passaram a ser amplamente utilizados no tratamento de duas condies que frequentemente caminham juntas: diabetes tipo 2 e obesidade

The enhancement was statistically significant in most dose comparisons, and no serious adverse events occurred

doi: 10.1146/annurev-food-041715-033159 38 KeshteliA

The resulting weight loss was a significant secondary benefit that has since become a primary treatment goal